CASE REPORT

Case Report: Drug induced hyperkalemia presenting as acute flaccid quadriparesis [version 1; peer review: awaiting peer review]

Santhosh Narayanan, Divya Prakash

Department of Cardiology, Government Medical College, Kozhikode, Kerala, 673008, India
Department of Pathology, JJM Medical College, Davangere, Karnataka, 577004, India

Abstract

Hyperkalemia is a life-threatening dyselectrolytemia that commonly affects cardiac conductivity and contractility. Ascending paralysis affecting the extremities associated with hyperkalemia is not commonly seen. Here we report a case of flaccid quadriparesis in a patient who was taking potassium sparing diuretic for cardiac disease. An electrocardiogram showed typical signs of hyperkalemia. The patient was administered antihyperkalemic measures, which led to a dramatic improvement in symptoms. Hyperkalemic paralysis is a completely reversible emergency condition and should always be considered when dealing with acute onset flaccid paralysis.

Keywords

Hyperkalemia, neuromuscular paralysis, Electrocardiography

Corresponding author: Santhosh Narayanan (drsanthosh4@gmail.com)

Author roles: Narayanan S: Conceptualization, Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; Prakash D: Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Narayanan S and Prakash D. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Narayanan S and Prakash D. Case Report: Drug induced hyperkalemia presenting as acute flaccid quadriparesis [version 1; peer review: awaiting peer review] F1000Research 2018, 7:737 (https://doi.org/10.12688/f1000research.15061.1)

Introduction

Hyperkalemia is a frequently encountered clinical problem. Hyperkalemic paralysis occurs primarily in genetic defects due to sodium channelopathy. Though numerous other etiologies can cause hyperkalemia, neuromuscular paralysis is unusual. Prompt diagnosis and management ensues complete and rapid reversal of symptoms. This atypical presentation is a challenge to the clinician. In the case presented herein, early initiation of treatment saved the patient without the need of invasive ventilation or hemodialysis.

Case report

A 66 year old man presented with a history of weakness of both lower extremities followed by weakness in the upper extremities for a duration of 12 hours. There was no history of numbness, paresthesia or sensory loss. The patient did not have any symptom suggestive of cranial nerve involvement, raised intracranial tension and autonomic dysfunction. He had a past history of coronary artery disease (anterior wall myocardial infarction with moderate left ventricular dysfunction) and had undergone percutaneous transluminal coronary angioplasty. The patient was taking Aspirin (75 mg once daily), Ramipril (2.5 mg once daily) and Spironolactone (25 mg once daily) for the past year.

On examination the patient was attentive, oriented and hemodynamically stable. Nervous system examination revealed hypotonia of all four limbs with a power of grade 2. Deep tendon reflexes were absent. Remaining neurological examination and other system examination were within normal limits. Clinically a possibility of acute inflammatory demyelinating polyradiculoneuropathy was considered. Laboratory investigations are depicted in Table 1.

An electrocardiogram (ECG) showed tall peaked T waves (Figure 1), prolonged PR interval and loss of P waves conspicuous of hyperkalemia (Figure 2). The patient was immediately initiated on antihyperkalemia measures, where the dose was guided by clinical response. Calcium gluconate, insulin-dextrose solution infusion, nebulization with beta 2 agonist and oral potassium binding agent (calcium polystyrene sulfonate) were administered. ACE inhibitors (Ramipril 2.5 mg once daily) and Spironolactone (25 mg once daily) were stopped. Arterial blood gas analysis revealed mild metabolic acidosis.

Serum potassium levels subsequently normalized after 12 hours of treatment. The patient showed rapid clinical improvement, without the requirement of haemodialysis. He was able to walk on the second day and on examination had grade 5 power in all limbs. An ECG taken after correction of hyperkalemia (after 12 hours of treatment) showed normal sinus rhythm. The patient was detected to have deranged renal function with evidence of chronic kidney disease using ultrasonography, which might have contributed to his hyperkalemia. A portable chest radiograph did not show evidence of fluid overload. Nerve conduction was normal.

On follow up after two months the patient was doing well without any neurological symptoms. His serum creatinine was 2.4 mg/dl and serum potassium was 4 meq/l. He is being monitored regularly by the nephrologist.

Discussion

Clinical manifestations of hyperkalemia are often nonspecific. Patients may present with vague aches and pains, muscle cramps, fatigue or sometimes palpitations. Cardiac arrhythmias are life threatening. Neuromuscular paralysis is not a common

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patient’s results</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>10.3 g/dl</td>
<td>14–16 mg/dl</td>
</tr>
<tr>
<td>Total leucocyte count</td>
<td>8000/cmm</td>
<td>4000–11,000/cmm</td>
</tr>
<tr>
<td>Platelet count</td>
<td>2.64 lakh/cmm</td>
<td>1.5–4 lakh/cmm</td>
</tr>
<tr>
<td>Random blood sugar</td>
<td>93 mg/dl</td>
<td>80–120 mg/dl</td>
</tr>
<tr>
<td>Blood urea</td>
<td>54 mg/dl</td>
<td>17–48 mg/dl</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>2.6 mg/dl</td>
<td>0.8–1.2 mg/dl</td>
</tr>
<tr>
<td>Serum sodium</td>
<td>134 meq/l</td>
<td>135–145 meq/L</td>
</tr>
<tr>
<td>Serum potassium</td>
<td>9.4 meq/l</td>
<td>3.5–5 meq/l</td>
</tr>
</tbody>
</table>

Figure 1. Electrocardiogram showing tall peaked T waves.
presentation of hyperkalemia and is frequently seen with hypokalemia. There are only isolated reports of hyperkalemia presenting as flaccid paralysis\textsuperscript{2,3}. Weakness in hyperkalemia occurs in an ascending manner, starting in the lower limbs and sometimes leads to respiratory distress requiring invasive ventilation. In the present case, weakness progressed rapidly, but did not involve the respiratory muscles and the patient improved without the need of respiratory support.

The exact molecular mechanism by which hyperkalemia produces neurological dysfunction is not yet elucidated. It is hypothesized to be due to abnormal membrane depolarization. Resting membrane potential of cell membranes is maintained by the difference in concentration of extracellular and intracellular potassium ions. When the extracellular potassium increases in hyperkalemia, it blunts the transmission of nerve impulse to muscle fiber\textsuperscript{4}.

In a report by Evers \textit{et al.}, renal dysfunction was the most common cause of secondary hyperkaemic paralysis, as in our case\textsuperscript{5}. Other etiologies include excessive dietary intake of potassium, metabolic acidosis, medications that inhibit the renin angiotensin aldosterone system, medications that cause transcellular shift of potassium (Digoxin) and increased tissue catabolism as in tumor lysis and trauma. Succinylcholine used for rapid sequence intubation can cause fatal hyperkalemia, and sometimes result in a similar presentation\textsuperscript{6}. Serial electrocardiographic changes in hyperkalemia are described by Aslam \textit{et al.},\textsuperscript{7} Electrocardiographic changes may not always correlate with degree of hyperkalemia.

**Conclusion**

The present case highlights the importance of considering hyperkalemia as a differential diagnosis in patients presenting with acute flaccid paralysis. Regular monitoring of serum potassium should be done in patients on potassium sparing diuretics and other potassium altering drugs. Patients with chronic kidney disease should be carefully watched for development of any complication of hyperkalemia.

**Consent**

Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

**Data availability**

All data underlying the results are available as part of the article and no additional source data are required.

**Competing interests**

No competing interests were disclosed.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.

---

**References**


Comments on this article

Version 1

Reader Comment 30 Mar 2019

Ny Cherry, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam

Hello,
I'm learning about drugs this case and see your report. thanks so much! But could you explain more detail about the drugs used in this case? I'm wondering the amount and frequency of drugs were administered. I'm looking forward to hearing from you. thanks!!

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com